Topline data were announced from a phase 3 trial investigating lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension.
The trial of the once-daily drug—which mimics a gut hormone known as GLP-1 to control blood sugar and suppress ...
Reported unprecedented, statistically significant reversal of compensated cirrhosis (F4) due to MASH after 96 weeks of treatment with efruxifermin (EFX) in Phase 2b SYMMETRY study -- -- Completed enro ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results